INVO Fertility (IVF) CFO reports Form 3 insider option grants
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
INVO Fertility, Inc. reported the initial holdings of its Chief Financial Officer, Terah Renee Krigsvold, as of 12/30/2025 on a Form 3. She directly holds 1 share of common stock and a series of stock options giving the right to purchase additional common shares.
The disclosed stock options cover small numbers of underlying common shares, including grants for 3, 3, 2, 2, 2, 11 and 4,375 shares, with stated exercise prices such as $17,683.2, $17,280, $2,304, $2,983.68, $3,882.24, $2,119.68 and $8.96. Footnotes explain that several options have vesting schedules based on monthly installments over 36 months or quarterly installments beginning in 2023 and, for the latest grant, on the first day of calendar quarters following August 26, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Krigsvold Terah Renee
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 3 shares (Direct);
Common Stock — 1 shares (Direct)
Footnotes (1)
- The option vested in monthly increments over a period of 36 months from January 1, 2021. The option vested in monthly increments over a period of 36 months from February 11, 2022. The option vests in 12 equal installments beginning on May 18, 2023 and on the last day of each calendar quarter thereafter until fully vested. The option vests in four equal installments beginning on the first day of the calendar quarter following August 26, 2025 and on the first day of each calendar quarter thereafter until fully vested.
FAQ
What does this Form 3 filing for INVO Fertility (IVF) show?
It shows the initial statement of beneficial ownership for Chief Financial Officer Terah Renee Krigsvold as of 12/30/2025, including her common stock and stock option holdings in INVO Fertility, Inc..
What stock options are reported for the INVO Fertility CFO on this Form 3?
The Form 3 lists several stock options (rights to buy common stock) covering 3, 3, 2, 2, 2, 11 and 4,375 underlying shares, each reported as held directly.
What are the exercise prices of the INVO Fertility CFO’s stock options?
The options have reported exercise prices including $17,683.2, $17,280, $2,304, $2,983.68, $3,882.24, $2,119.68 and $8.96 for the various grants.
How do the INVO Fertility CFO’s stock options vest?
Footnotes state that some options vested in monthly increments over 36 months starting January 1, 2021 or February 11, 2022, while others vest in 12 equal quarterly installments beginning May 18, 2023 or in four equal quarterly installments starting on the first day of the calendar quarter after August 26, 2025.
Is the INVO Fertility CFO’s ownership direct or through another entity?
The Form 3 marks all reported holdings, including the 1 common share and all listed stock options, as held directly (D), with no separate indirect ownership entity noted.